Cancer Health Outcomes and Control Research Program (CO) (Project-007)

项目007--癌症健康结果和控制研究计划 项目摘要/摘要 癌症健康结果和控制研究计划(CO)的首要使命是促进 1)改善有癌症诊断或有癌症风险的患者和家庭的预后的研究；2) 在整个癌症护理过程中减少恶性肿瘤的公共卫生负担。一氧化碳研究是 分为三个主题领域：1)健康和高危人群的预防和早期发现；2) 与癌症治疗相关的治疗结果；3)生存和姑息治疗。CO支持 通过以下具体目标在这三个领域进行研究，目的是将 向诊所和社区进行研究，以满足我们的使命： ·建立和进一步发展以人口和社区为基础的研究资源，重点是 癌症预防、及早发现和改善预后 ·评估癌症诊断和发展后以患者为中心的短期和长期结果 改善结果的战略 ·确定影响癌症预防、治疗和结果的社会行为因素 ·评估癌症健康结果和控制方面差异的大小和决定因素 与年龄、种族、性别、地理和其他群体特征相关联，并制定战略 缩小这种差距 来自10个部门和5所学校的26名计划成员获得了NCI 410万美元的资金和 460万美元的其他同行评议的癌症相关资金。在310份出版物中，13%是方案内出版物和 32%是跨程序的。会员还与其他网站的调查人员合作出版了106份出版物 机构。

PROJECT 007 – CANCER HEALTH OUTCOMES AND CONTROL RESEARCH PROGRAM PROJECT SUMMARY/ABSTRACT The overarching mission of the Cancer Health Outcomes and Control Research Program (CO) is to foster research that 1) improves outcomes for patients and families with or at risk for a cancer diagnosis and 2) reduces the public health burden of malignancies across the entire cancer care continuum. Research in CO is categorized into three thematic domains: 1) prevention and early detection in healthy and at-risk individuals; 2) treatment-related outcomes around cancer therapy and; 3) survivorship and palliative care. CO supports research across these three domains through the following specific aims, with the goal of translating that research to the clinic and community to meet our mission: • To establish and further develop population and community-based resources for research focused on cancer prevention, early detection and improved outcomes • To assess short- and long-term patient-centered outcomes following a cancer diagnosis and develop strategies to improve outcomes • To identify socio-behavioral factors influencing cancer prevention, treatment and outcomes • To assess the magnitude and determinants of disparities in cancer health outcomes and control associated with age, race, gender, geography and other group characteristics and develop strategies to decrease such disparities There are 26 program members from ten departments and five schools with $4.1M in NCI funding and $4.6M in other peer-reviewed cancer-related funding. Out of 310 publications, 13% are intra-programmatic and 32% are inter-programmatic. Members also have 106 collaborative publications with investigators at other institutions.